DK2467401T3 - Antistoffer til påvisningen af integrinkomplekser i ffpe materiale - Google Patents

Antistoffer til påvisningen af integrinkomplekser i ffpe materiale Download PDF

Info

Publication number
DK2467401T3
DK2467401T3 DK10749593.9T DK10749593T DK2467401T3 DK 2467401 T3 DK2467401 T3 DK 2467401T3 DK 10749593 T DK10749593 T DK 10749593T DK 2467401 T3 DK2467401 T3 DK 2467401T3
Authority
DK
Denmark
Prior art keywords
seq
antibody
cdr
amino acid
integrin
Prior art date
Application number
DK10749593.9T
Other languages
English (en)
Inventor
Simon Goodman
Claudia Wilm
Francesc Mitjans
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK2467401T3 publication Critical patent/DK2467401T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (8)

1. Monoklonalt antistof opnået ved immunisering af en kanin med et rekombinant immunogen bestående af et ekstracellulært integrindomæne med insekt-afledt glycosyleringsmønster med en aminosyresekvens af SEQ ID NO: 10 (DTM-avB5), 90 (DTM-avB3), 130 (DTM-avB6), 170 (DTM-avB8) eller 210 (DTM-αν), hvor antistoffet er i stand til at binde til intakte heterodimerer af henholdsvis integrin avB5, integrin av63, integrin avB6, integrin avB8 og integrin med kæde av i formalin-fikseret paraffin indlejret (FFPE)-materiale, i en isoleret form i ELISA og på levedygtige celler med i det væsentlige samme specificitet.
2. Antistof ifølge krav 1, hvor antistoffet omfatter en let kæde variabel region (Vl) omfattende en aminosyresekvens af SEQ ID NO: 15 (Vi.-avB5) og en tung kæde variabel region (Vh) omfattende en aminosyresekvens af SEQ ID NO: 16 (VH-avB5).
3. Antistof ifølge krav i, hvor antistoffet omfatter en let kæde variabel region (Vl) omfattende en aminosyresekvens af SEQ ID NO: 95 (VL-avB3) og en tung kæde variabel region (Vh) omfattende en aminosyresekvens af SEQ ID NO: 96 (VH-avB3).
4. Antistof ifølge krav 1, hvor antistoffet omfatter en let kæde variabel region (Vl) omfattende en aminosyresekvens af SEQ ID NO: 135 (Vl-ovB6) og en tung kæde variabel region (Vh) omfattende en aminosyresekvens af SEQ ID NO: 136 (Vh-ovB6)
5. Antistof ifølge krav 1, hvor antistoffet omfatter en let kæde variabel region (Vl) omfattende en aminosyresekvens af SEQ ID NO: 175 (Vl-ovB8) og en tung kæde variabel region (Vh) omfattende en aminosyresekvens af SEQ ID NO: 176 (VH-avB8).
6. Antistof ifølge krav 1, hvor antistoffet omfatter en let kæde variabel region (Vl) omfattende en aminosyresekvens af SEQ ID NO: 215 (Vl-ov) og en tung kæde variabel region (Vh) omfattende en aminosyresekvens af SEQ ID NO: 216 (Vh-qv).
7. Polynukleotid der koder for antistoffet ifølge et hvilket som helst af kravene 1 til 6.
8. Anvendelse af antistoffet ifølge et hvilket som helst af kravene 1 til 6 til påvisningen af integriner i formalin-fikseret paraffin indlejret (FFPE)-materiale.
DK10749593.9T 2009-08-19 2010-07-15 Antistoffer til påvisningen af integrinkomplekser i ffpe materiale DK2467401T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09010666 2009-08-19
PCT/EP2010/004313 WO2011020529A2 (en) 2009-08-19 2010-07-15 Antibodies for the detection of integrin complexes in ffpe material

Publications (1)

Publication Number Publication Date
DK2467401T3 true DK2467401T3 (da) 2017-03-20

Family

ID=42813245

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10749593.9T DK2467401T3 (da) 2009-08-19 2010-07-15 Antistoffer til påvisningen af integrinkomplekser i ffpe materiale

Country Status (18)

Country Link
US (2) US8420348B2 (da)
EP (1) EP2467401B1 (da)
JP (1) JP5734978B2 (da)
KR (1) KR101606236B1 (da)
CN (1) CN102597001B (da)
AU (1) AU2010285265B2 (da)
BR (1) BR112012003686B1 (da)
CA (1) CA2771441C (da)
DK (1) DK2467401T3 (da)
EA (1) EA032728B1 (da)
ES (1) ES2622487T3 (da)
HK (1) HK1173455A1 (da)
IL (1) IL218119A (da)
MX (1) MX2012001741A (da)
PT (1) PT2467401T (da)
SG (1) SG178348A1 (da)
WO (1) WO2011020529A2 (da)
ZA (1) ZA201201990B (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2570731T3 (es) 2008-08-05 2016-05-20 Toray Industries Método de detección de cáncer
RU2498819C2 (ru) 2008-08-05 2013-11-20 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и профилактики злокачественных опухолей
DK2532367T3 (da) 2010-02-04 2018-11-19 Toray Industries Farmaceutisk middel til behandling og/eller forebyggelse af cancer
US8828398B2 (en) 2010-02-04 2014-09-09 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
MX340014B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
PT2672994T (pt) 2011-02-11 2018-10-22 Merck Patent Gmbh Anticorpo anti-integrina alfa-v para o tratamento do cancro da próstata
PT2740489T (pt) 2011-08-04 2017-01-10 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático
PL2740798T3 (pl) 2011-08-04 2017-07-31 Toray Industries, Inc. Kompozycja leku do leczenia i/lub zapobiegania nowotworom
PT2741085T (pt) 2011-08-04 2017-06-30 Toray Industries Método para a deteção de cancro prancreático
AU2012290955B2 (en) 2011-08-04 2017-04-27 Toray Industries, Inc. Drug composition for cancer treatment and/or prevention
KR101980557B1 (ko) 2011-08-04 2019-05-21 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
JP6065591B2 (ja) 2011-08-04 2017-01-25 東レ株式会社 癌の治療及び／又は予防用医薬組成物
HUE047006T2 (hu) 2011-08-04 2020-04-28 Toray Industries Anti-caprin-1 antitesteket tartalmazó gyógyászati kompozíció rák kezelésére és/vagy megelõzésére
CN103857696B (zh) * 2011-08-17 2017-07-04 加利福尼亚大学董事会 结合整合素αVβ8的抗体
HUE045461T2 (hu) 2012-02-21 2019-12-30 Toray Industries Gyógyászati készítmény rák kezelésére
BR112014021101A2 (pt) 2012-02-21 2022-03-22 Toray Industries Anticorpo, composição farmacêutica, droga de combinação, dna e método de tratamento e/ou prevenção de câncer, uso de um anticorpo
AU2013223161B2 (en) 2012-02-21 2017-10-19 Toray Industries, Inc. Medicinal composition for treating and/or preventing cancer
DK2818481T3 (da) 2012-02-21 2019-10-14 Toray Industries Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
RU2640245C2 (ru) 2012-03-30 2017-12-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или предотвращения рака печени
AU2013241043B2 (en) 2012-03-30 2017-11-09 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gall bladder cancer
BR112015001100A2 (pt) 2012-07-19 2018-03-27 Toray Industries, Inc. método de detecção de câncer
KR102056654B1 (ko) 2012-07-19 2019-12-17 도레이 카부시키가이샤 암의 검출 방법
GB2533173A (en) 2013-08-05 2016-06-15 Twist Bioscience Corp De Novo synthesized gene libraries
WO2015020212A1 (ja) * 2013-08-09 2015-02-12 東レ株式会社 癌の治療及び／又は予防用医薬組成物
ES2754282T3 (es) 2014-02-14 2020-04-16 Bioventures Llc Aductos acetaminofén proteína y procedimientos de uso de los mismos
WO2016026956A1 (en) * 2014-08-22 2016-02-25 Baxalta GmbH Detection of cho-mif contaminations
EP3009147A1 (en) 2014-10-16 2016-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant glioblastoma
US10570216B2 (en) 2014-12-03 2020-02-25 Bioventures, Llc Anti-acetaminophen antibodies and acetaminophen protein adducts
US10669304B2 (en) 2015-02-04 2020-06-02 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
WO2016172377A1 (en) 2015-04-21 2016-10-27 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
EA201890763A1 (ru) 2015-09-18 2018-08-31 Твист Байосайенс Корпорейшн Библиотеки вариантных олигонуклеиновых кислот и их синтез
KR20180058772A (ko) 2015-09-22 2018-06-01 트위스트 바이오사이언스 코포레이션 핵산 합성을 위한 가요성 기판
WO2017182834A1 (en) 2016-04-19 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating resistant glioblastoma
CN110248724B (zh) 2016-09-21 2022-11-18 特韦斯特生物科学公司 基于核酸的数据存储
US11550939B2 (en) 2017-02-22 2023-01-10 Twist Bioscience Corporation Nucleic acid based data storage using enzymatic bioencryption
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
GB2578844A (en) 2017-06-12 2020-05-27 Twist Bioscience Corp Methods for seamless nucleic acid assembly
CA3075505A1 (en) 2017-09-11 2019-03-14 Twist Bioscience Corporation Gpcr binding proteins and synthesis thereof
WO2019079769A1 (en) 2017-10-20 2019-04-25 Twist Bioscience Corporation HEATED NANOWELLS FOR THE SYNTHESIS OF POLYNUCLEOTIDES
US11820823B2 (en) * 2017-10-27 2023-11-21 Kite Pharma, Inc. T cell receptor antigen binding molecules and methods of use thereof
KR20210013128A (ko) 2018-05-18 2021-02-03 트위스트 바이오사이언스 코포레이션 핵산 하이브리드화를 위한 폴리뉴클레오타이드, 시약 및 방법
CA3107137A1 (en) * 2018-09-07 2020-03-12 Pfizer Inc. Anti-avb8 antibodies and compositions and uses thereof
EP3898959A4 (en) * 2018-12-21 2023-01-11 Board of Regents, The University of Texas System PHOSPHORYLATED DICER ANTIBODY AND METHODS OF USE THEREOF
CN113287013A (zh) * 2019-01-04 2021-08-20 国立大学法人京都大学 溃疡性大肠炎以及原发性硬化性胆管炎的检查方法
WO2020176680A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
EP3987019A4 (en) 2019-06-21 2023-04-19 Twist Bioscience Corporation BARCODE-BASED NUCLEIC ACID SEQUENCE ARRANGEMENT
EP3994167A4 (en) * 2019-07-02 2023-11-01 Astute Medical, Inc. ANTIBODIES AND ASSAY FOR CCL14
EP4010369A4 (en) * 2019-08-09 2023-11-22 The Board of Trustees of the Leland Stanford Junior University THERAPEUTIC ANTIBODIES AGAINST OSTEOPONTIN
JP2022548783A (ja) * 2019-09-23 2022-11-21 ツイスト バイオサイエンス コーポレーション 単一ドメイン抗体のバリアント核酸ライブラリー
CN114828887A (zh) * 2019-12-05 2022-07-29 思进公司 抗-αVβ6抗体和抗体-药物偶联物
CN114907468B (zh) * 2022-06-10 2023-05-23 东莞理工学院 一种仿刺参整合素多克隆抗体、抗原蛋白及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005155A1 (en) * 1987-11-19 1989-06-15 Scripps Clinic And Research Foundation Monoclonal antibody against the rgd-directed adhesion receptor of endothelial cells
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти
WO1997010796A2 (en) * 1995-09-01 1997-03-27 Ramot-University Authority For Applied Research And Industrial Development Ltd. MANIPULATION AND DETECTION OF PROTEIN PHOSPHATASE 2C - PP2Cα - EXPRESSION IN TUMOR CELLS FOR CANCER THERAPY, PREVENTION AND DETECTION
AU5150499A (en) 1998-06-02 1999-12-20 Imtox Gmbh Rationally designed peptides, production and use thereof
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
ES2292638T3 (es) 2000-11-08 2008-03-16 Fresenius Medical Care Affina Gmbh Peptidos, su preparacion y su uso para la union a inmunoglobulinas.
US20030087250A1 (en) * 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
EP1487492A4 (en) 2002-03-04 2008-10-01 Medimmune Inc PREVENTION OR TREATMENT OF CANCER USING INTEGRIN ALPHAVBETA3 ANTAGONISTS COMBINED WITH OTHER AGENTS
ME00804B (me) * 2002-03-13 2012-03-20 Biogen Idec Inc Anti-alpha v beta 6 antitela
US20040048312A1 (en) * 2002-04-12 2004-03-11 Ronghao Li Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
AU2003256584A1 (en) * 2002-07-17 2004-02-02 The Center For Blood Research, Inc. Modified proteins stabilized in a desired conformation and methods for producing same
CN1444043A (zh) * 2002-12-25 2003-09-24 帕弗瑞生物技术(北京)有限公司 一种个体化特异性免疫细胞功能测定方法
SE0301087D0 (sv) * 2003-04-14 2003-04-14 Cartela Ab New monoclonal antibody
US7429487B2 (en) 2005-07-05 2008-09-30 Epitomics, Inc. Fusion partner for production of monoclonal rabbit antibodies
EA200870130A1 (ru) * 2005-12-30 2009-02-27 Мерк Патент Гмбх Антитела против ил-6, предотвращающие связывание с gp130 комплекса ил-6 и альфа-рецептора ил-6
EP2167128B1 (en) 2007-07-17 2012-10-24 Merck Patent GmbH Engineered anti-alpha v- integrin hybrid antibodies

Also Published As

Publication number Publication date
KR101606236B1 (ko) 2016-03-24
ES2622487T3 (es) 2017-07-06
CA2771441A1 (en) 2011-02-24
JP2013502205A (ja) 2013-01-24
US20130203079A1 (en) 2013-08-08
CN102597001A (zh) 2012-07-18
EP2467401A2 (en) 2012-06-27
AU2010285265A2 (en) 2012-06-07
ZA201201990B (en) 2012-11-28
IL218119A (en) 2015-08-31
HK1173455A1 (en) 2013-05-16
BR112012003686A2 (pt) 2016-03-29
SG178348A1 (en) 2012-03-29
WO2011020529A8 (en) 2011-04-21
JP5734978B2 (ja) 2015-06-17
AU2010285265B2 (en) 2015-05-21
BR112012003686B1 (pt) 2021-09-21
AU2010285265A1 (en) 2012-04-05
EA201200281A1 (ru) 2012-09-28
CA2771441C (en) 2016-10-11
US20120171699A1 (en) 2012-07-05
EP2467401B1 (en) 2017-01-18
KR20120059556A (ko) 2012-06-08
EA032728B1 (ru) 2019-07-31
WO2011020529A2 (en) 2011-02-24
WO2011020529A3 (en) 2011-06-16
MX2012001741A (es) 2012-03-21
CN102597001B (zh) 2014-07-30
PT2467401T (pt) 2017-04-26
US8993261B2 (en) 2015-03-31
IL218119A0 (en) 2012-04-30
US8420348B2 (en) 2013-04-16

Similar Documents

Publication Publication Date Title
DK2467401T3 (da) Antistoffer til påvisningen af integrinkomplekser i ffpe materiale
EP2501724B1 (en) Monoclonal antibodies and diagnostic uses thereof
US9823251B2 (en) Anti-Uroplakin II antibodies systems and methods
CN115667304A (zh) 抗人lag-3抗体及其在免疫组织化学(ihc)中的用途
US10179815B2 (en) Antibodies specifically binding to HER3
CN116410322A (zh) 抗人pcdh7蛋白的单克隆抗体及其应用
TWI782000B (zh) 抗ｇｐｒ２０抗體、其製造方法及其應用
CN112250767B (zh) 一种结合Strep-Tag II标签的抗体及其应用
EP4337679A2 (en) Mertk peptides and uses thereof
CN116234823A (zh) 用于在免疫组织化学（ihc）方案中诊断癌症的抗体
JP2003055399A (ja) 抗形質膜シアリダーゼ単クローン抗体
AU2015224525A1 (en) Monoclonal antibodies and diagnostic uses thereof